Clementia Pharmaceuticals Inc (CMTA) Shares Sold by United Services Automobile Association

United Services Automobile Association decreased its holdings in shares of Clementia Pharmaceuticals Inc (NASDAQ:CMTA) by 7.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 76,106 shares of the company’s stock after selling 5,685 shares during the period. United Services Automobile Association owned approximately 0.24% of Clementia Pharmaceuticals worth $895,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of CMTA. Trexquant Investment LP bought a new stake in shares of Clementia Pharmaceuticals in the 3rd quarter valued at $126,000. Northern Trust Corp increased its position in shares of Clementia Pharmaceuticals by 16.8% in the 4th quarter. Northern Trust Corp now owns 16,211 shares of the company’s stock valued at $191,000 after buying an additional 2,335 shares in the last quarter. Opaleye Management Inc. bought a new stake in shares of Clementia Pharmaceuticals in the 3rd quarter valued at $1,660,000. Birchview Capital LP increased its position in shares of Clementia Pharmaceuticals by 82.0% in the 4th quarter. Birchview Capital LP now owns 222,000 shares of the company’s stock valued at $2,611,000 after buying an additional 100,000 shares in the last quarter. Finally, Fosun International Ltd bought a new stake in shares of Clementia Pharmaceuticals in the 4th quarter valued at $2,627,000. Institutional investors own 78.72% of the company’s stock.

Shares of Clementia Pharmaceuticals stock traded down $0.03 during trading hours on Friday, reaching $26.35. 716,706 shares of the company’s stock were exchanged, compared to its average volume of 145,059. Clementia Pharmaceuticals Inc has a fifty-two week low of $8.10 and a fifty-two week high of $26.73. The company has a market cap of $1.00 billion, a price-to-earnings ratio of -3.32 and a beta of 0.64.

CMTA has been the subject of a number of recent analyst reports. Robert W. Baird initiated coverage on shares of Clementia Pharmaceuticals in a research report on Friday, January 18th. They issued an “outperform” rating and a $24.00 price objective for the company. Zacks Investment Research lowered shares of Clementia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, February 12th. Wedbush lowered shares of Clementia Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Monday, February 25th. ValuEngine raised shares of Clementia Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, February 25th. Finally, Svb Leerink lowered shares of Clementia Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $26.00 target price for the company. in a research note on Tuesday, February 26th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Clementia Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $25.00.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/clementia-pharmaceuticals-inc-cmta-shares-sold-by-united-services-automobile-association.html.

Clementia Pharmaceuticals Company Profile

Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial.

Featured Article: What is Blockchain?

Institutional Ownership by Quarter for Clementia Pharmaceuticals (NASDAQ:CMTA)

Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.